Bucharest - May 8, 2014 - Patients can still enroll in clinical trials Selic-V Weinheim / Germany,

All (6196) Public Administration (137) Business (4140) Agriculture (255) Architecture / Design (41) Arts & Entertainment (451) Auto (269) Law (435) Banking / Insurance (390) Construction (266) Education / Culture (496) Energy (160) Events (1617) Finance / Accounting (194) IT & C (712) Real Estate (95) Industry (214) Justice (356) Media / Advertising (751) Environment (289) Gossip / Lifestyle (222) NGO (38) Oil (180) Politics (79) Religion (21) Health (622) Social (2295) Sports (265) Science / Research (78) Technology (334) Travel (297)
Bucharest - May 8, 2014 - Patients can still enroll in clinical trials Selic-V Weinheim / Germany, May 24, 2014 - neonates and children up to 5 years with deficiency of ornithine transcarbamylase (OCT), carbamyl phosphate synthetase (CPS I) or argininosuccinate synthetase (ASS) (citrulinemie type I) can participate in the clinical trial Selic V1 on liver cells. The purpose of this open-label trial and multicentric future is to demonstrate the safety and efficacy of liver cells in children who suffer from congenital defects of the urea cycle mentioned above. Preliminary analysis of clinical data presented at the annual conference of the Association for Paediatric Metabolic Deficiency (APS) which avult held in Fulda / Germaia shows an expected improvement in patients with liver cells. "These preliminary results rachael ray motivate us to continue our research in 2014, providing seriously ill children the chance to gain more time to reach liver transplantation, among others," said study director, Professor Dr. Georg F. Hoffmann at Children's Hospital of the University of Heidelberg. Cytonet rachael ray has applied to the European Medicines Agency in December 2013 for approval of liver cell therapy. 1 The safety and efficacy of liver cells have deficient patients suffering from urea cycle you wish to enroll in the program Selic study on liver cell therapy? You can get more details on the criteria for inclusion or exclusion in the study of the Director of Research at Heidelberg University Hospital: Prof. Dr. med. Prof. hc (RCH) Georg Friedrich Hoffmann Heidelberg University Hospital, Im Neuenheimer Feld Pediatric Clinic I 430 69120 Heidelberg / Germany Phone: +49 (0) 6221 - 56-4101 E-Mail: georg.hoffmann @ med.uni-heidelberg About urea cycle defects and liver cell therapy urea cycle defects is serious deficiencies, potentially deadly in the metabolism of ammonia (NH3) by the liver. These include deficiencies of carbamyl phosphate synthetase type I (CPS I), N-acetyl rachael ray glutamate synthetase (NAGS), ornithine transcarbamylase (OCT), rachael ray argininosuccinate synthetase (ASS) - also called citrulinemie rachael ray - argininosuccinaza (ASL) and arginase-1 (hiperargininemie). Urea cycle defects occur when different enzymes that are designed to remove ammonia from the body are inhibited. In patients affected by these deficiencies, ammonia and urea are not metabolized in the body is excreted through urine but accumulates in the blood and tissues, and depending on the severity of the disease can lead to severe neuronal disorders, brain damage and even death . Normal physical and mental development is impossible rachael ray in children with untreated urea cycle deficiencies. Since the only available treatment for newborns - transplatul liver or liver lobe - is very problematic and suitable transplant organs are very rare in recent rachael ray years has studied and developed the treatment of liver cells isolated from donors. Cytonet centers work closely with neonatal rachael ray and pediatric metabolism internationally. The ultimate goal is to compensate rachael ray for metabolic deficiency by transplanting healthy cells. The project is funded rachael ray by the German Ministry of Education and Research Cluster of Excellence in the competition. Cytonet is an active partner in the Biotech-Cluster-Rhein-Neckar (BioRN) has received the Award of Excellence in Cellular and Molecular Medicine in 2008. About Cytonet Cytonet rachael ray Group is an international biotechnology rachael ray with 60 employees and headquarters in Weinheim, Heidelberg in Germany and in Durham, North Carolina, USA. The company develops products and cellular therapies using human cells. In many diseases, these products offer an alternative to existing treatments such as organ transplantation, or prolong a patient's life until the transplant. Liver cell therapy developed by Cytonet involve a complex procedure of isolation rachael ray and preparation of liver cells that do not meet the criteria for transplantation. Dr. Wolfgang RüDINGER, Dipl.-Kfm. Michael J. Deissner and Dr. Torsten Hombeck are company executives. Cytonet emerged from the cell therapy division of Roche and was founded in April 2000. Co.